Brooks Michael J 4

What Happened

• Michael J. Brooks, President of Edesa Biotech, was granted 64,609 restricted share units (RSUs) on May 27, 2026. The award shows an acquisition price of $0.00 (no cash paid at grant).
• This is an equity award (grant), not an open-market purchase or sale, so it reflects compensation rather than an outright buying/selling signal.

Key Details

• Transaction date: 2026-05-27; Form 4 filed: 2026-05-29.
• Transaction type/code: Grant/Award (code A); 64,609 RSUs acquired at $0.00.
• Vesting: RSUs vest monthly in equal proportions over 36 months, commencing on the grant date (per footnote).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• No indication in the excerpt that the filing was late.

Context

• RSUs are restricted stock units that convert to shares (or are settled) only as they vest; they do not represent immediately tradable shares.
• Because this is a compensation grant, it should be viewed as part of executive pay rather than a direct bullish or bearish insider market signal.
• Retail investors tracking insider activity often give more weight to purchases than to compensation grants; vesting schedule determines when these RSUs could become shareable.